GSK1363089 (XL880)

GSK1363089 · GlaxoSmithKline

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for GSK1363089 (XL880), covering 2017-07-31 to 2017-12-11. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) [Phase 2]